Nephros, Inc. (NEPH)
NASDAQ: NEPH · IEX Real-Time Price · USD
2.060
-0.090 (-4.19%)
Jul 2, 2024, 4:30 PM EDT - Market closed

Nephros Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Nephros stock has a target of 5.00, which predicts an increase of 142.72% from the current stock price of 2.06.

Analyst Consensus: Buy
Target Low Average Median High
Price $5.00 $5.00 $5.00 $5.00
Change +142.72% +142.72% +142.72% +142.72%
* Price targets were last updated on May 15, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for Nephros is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Apr '24May '24Jun '24
Strong Buy 000
Buy 111
Hold 000
Sell 000
Strong Sell 000
Total 111

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Benchmark
Benchmark
Buy
Reiterates
$5
Buy Reiterates $5 +142.72% May 15, 2024
Benchmark
Benchmark
Buy
Upgrades
$5
Buy Upgrades $5 +142.72% Mar 8, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
16.31M
from 14.24M
Increased by 14.55%
Revenue Next Year
18.42M
from 16.31M
Increased by 12.91%
EPS This Year
-0.04
from -0.15
EPS Next Year
0.04
from -0.04
Year 2019202020212022202320242025
Revenue
10.33M8.56M10.22M9.98M14.24M16.31M18.42M
Revenue Growth
81.71%-17.16%19.34%-2.37%42.74%14.55%12.91%
EPS
-0.45-0.52-0.39-0.70-0.15-0.040.04
EPS Growth
-------
Forward PE
------50.49
No. Analysts -----43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20242025
High 17.1M 19.0M
Avg 16.3M 18.4M
Low 15.4M 17.7M

Revenue Growth

Revenue Growth 20242025
High
20.1%
16.2%
Avg
14.6%
12.9%
Low
8.1%
8.5%

EPS Forecast

EPS 20242025
High -0.03 0.04
Avg -0.04 0.04
Low -0.04 0.04

EPS Growth

EPS Growth 20242025
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.